Klumpke's paralysis

Summary

Klumpke’s paralysis (MONDO:0023054) is a disease. A subtype of palsy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	klumpke’s paralysis
Mondo ID	MONDO:0023054
NCIT	C116724
SNOMED CT	83886009
UMLS	C0270898
MedGen	124376
GARD	0003123
Is cancer (heuristic)	no

Also known as: Dejerine Klumpke Palsy · Dejerine-Klumpke Palsy · Dejerine-Klumpke palsy · Klumpke Palsy · Klumpke Paralysis · Klumpke paralysis · Klumpke’s Palsy · Klumpke’s palsy · klumpke’s paralysis · Klumpke-DC)jerine brachial plexus injury · Klumpke-DC)jerine paralysis · klumpke-dC)jerine paralysis · Klumpke-Dejerine paralysis · Klumpkes Palsy · Lower Brachial Plexus Palsy · Lower brachial plexus palsy · Palsy, Dejerine-Klumpke · Palsy, Klumpke’s · Paralysis of the Lower Brachial Plexus · Paralysis, Klumpke

Disease family

This is a subtype of palsy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › palsy › klumpke’s paralysis

Related subtypes (9): hemiplegia, quadriplegia, facial paralysis, ophthalmoplegia, paraplegia, cerebral palsy, progressive bulbar palsy, respiratory paralysis, Erb palsy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.